Analysts expect that Sesen Bio, Inc. (NASDAQ:SESN – Get Rating) will post ($0.09) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Sesen Bio’s earnings, with the highest EPS estimate coming in at ($0.05) and the lowest estimate coming in at ($0.13). Sesen Bio reported earnings per share of ($0.07) during the same quarter last year, which would suggest a negative year-over-year growth rate of 28.6%. The firm is scheduled to report its next quarterly earnings results on Monday, January 1st.
On average, analysts expect that Sesen Bio will report full-year earnings of ($0.32) per share for the current fiscal year, with EPS estimates ranging from ($0.44) to ($0.19). For the next financial year, analysts expect that the company will post earnings of ($0.27) per share, with EPS estimates ranging from ($0.35) to ($0.19). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Sesen Bio.
Sesen Bio (NASDAQ:SESN – Get Rating) last announced its quarterly earnings results on Monday, February 28th. The company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.08) by $0.10. The firm had revenue of $20.00 million during the quarter.
Shares of Sesen Bio stock opened at $0.49 on Monday. The stock has a market capitalization of $98.63 million, a P/E ratio of 1.98 and a beta of 0.92. The stock has a 50 day moving average price of $0.54 and a two-hundred day moving average price of $0.73. Sesen Bio has a 12-month low of $0.37 and a 12-month high of $6.04.
A number of institutional investors have recently bought and sold shares of the stock. BlackRock Inc. boosted its holdings in Sesen Bio by 23.3% during the fourth quarter. BlackRock Inc. now owns 13,488,604 shares of the company’s stock worth $10,994,000 after buying an additional 2,553,282 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Sesen Bio by 72.1% during the 4th quarter. Geode Capital Management LLC now owns 4,511,761 shares of the company’s stock worth $3,677,000 after purchasing an additional 1,890,771 shares during the last quarter. Morgan Stanley boosted its stake in shares of Sesen Bio by 243.1% during the 3rd quarter. Morgan Stanley now owns 653,437 shares of the company’s stock worth $518,000 after acquiring an additional 462,991 shares during the period. Renaissance Technologies LLC bought a new position in shares of Sesen Bio during the 1st quarter worth approximately $276,000. Finally, Goldman Sachs Group Inc. boosted its stake in shares of Sesen Bio by 198.6% during the 4th quarter. Goldman Sachs Group Inc. now owns 606,862 shares of the company’s stock worth $495,000 after acquiring an additional 403,606 shares during the period. Institutional investors and hedge funds own 24.29% of the company’s stock.
Sesen Bio Company Profile (Get Rating)
Sesen Bio, Inc, a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer; to treat non-muscle invasive carcinoma in situ of the bladder in patients previously treated with BCG; and for the treatment of squamous cell carcinoma of the head and neck, as well as VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule-positive solid tumors.
- Get a free copy of the StockNews.com research report on Sesen Bio (SESN)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Will John Deere’s Earnings Help to Calm the Markets?
- Lowe’s Companies Has Not Bottomed
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sesen Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sesen Bio and related companies with MarketBeat.com's FREE daily email newsletter.